Is CytoMed Therapeutics Stock a Good Investment?
CytoMed Therapeutics Investment Advice | GDTC |
- Examine CytoMed Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research CytoMed Therapeutics' leadership team and their track record. Good management can help CytoMed Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact CytoMed Therapeutics' business and its evolving consumer preferences.
- Compare CytoMed Therapeutics' performance and market position to its competitors. Analyze how CytoMed Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if CytoMed Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about CytoMed Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in CytoMed Therapeutics Limited stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if CytoMed Therapeutics Limited is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine CytoMed Therapeutics Stock
Researching CytoMed Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 69.0% of the company shares are held by company insiders. The book value of CytoMed Therapeutics was currently reported as 0.88. The company recorded a loss per share of 0.22. CytoMed Therapeutics had not issued any dividends in recent years.
To determine if CytoMed Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding CytoMed Therapeutics' research are outlined below:
| CytoMed Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 290.56 K. Net Loss for the year was (3.13 M) with profit before overhead, payroll, taxes, and interest of 355.19 K. | |
| CytoMed Therapeutics generates negative cash flow from operations | |
| About 69.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: CytoMed Therapeutics signs Business Research Collaboration Agreement with Indias SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India |
CytoMed Therapeutics Quarterly Good Will |
|
CytoMed Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in CytoMed Therapeutics Limited. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to CytoMed Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of May 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact CytoMed Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises CytoMed Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-17 | 2023-09-30 | -0.06 | -0.08 | -0.02 | 33 |
CytoMed Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 26.17 M.Market Cap |
|
CytoMed Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.31) | |
| Return On Capital Employed | (0.29) | (0.30) | |
| Return On Assets | (0.29) | (0.31) | |
| Return On Equity | (0.42) | (0.45) |
Determining CytoMed Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if CytoMed Therapeutics is a good buy. For example, gross profit margin measures CytoMed Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of CytoMed Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of CytoMed Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CytoMed Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CytoMed Therapeutics' management manipulating its earnings.
Basic technical analysis of CytoMed Stock
As of the 22nd of January, CytoMed Therapeutics shows the Risk Adjusted Performance of 0.058, mean deviation of 6.01, and Downside Deviation of 7.73. CytoMed Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.CytoMed Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CytoMed Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on CytoMed Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CytoMed Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Choo Chee Kong over a year ago CytoMed Therapeutics exotic insider transaction detected |
Understand CytoMed Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing CytoMed Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.058 | |||
| Market Risk Adjusted Performance | 0.3172 | |||
| Mean Deviation | 6.01 | |||
| Semi Deviation | 7.13 | |||
| Downside Deviation | 7.73 | |||
| Coefficient Of Variation | 1721.88 | |||
| Standard Deviation | 8.71 | |||
| Variance | 75.87 | |||
| Information Ratio | 0.0539 | |||
| Jensen Alpha | 0.4531 | |||
| Total Risk Alpha | 0.2225 | |||
| Sortino Ratio | 0.0607 | |||
| Treynor Ratio | 0.3072 | |||
| Maximum Drawdown | 60.9 | |||
| Value At Risk | (10.60) | |||
| Potential Upside | 12.99 | |||
| Downside Variance | 59.71 | |||
| Semi Variance | 50.91 | |||
| Expected Short fall | (6.89) | |||
| Skewness | 1.02 | |||
| Kurtosis | 5.1 |
| Risk Adjusted Performance | 0.058 | |||
| Market Risk Adjusted Performance | 0.3172 | |||
| Mean Deviation | 6.01 | |||
| Semi Deviation | 7.13 | |||
| Downside Deviation | 7.73 | |||
| Coefficient Of Variation | 1721.88 | |||
| Standard Deviation | 8.71 | |||
| Variance | 75.87 | |||
| Information Ratio | 0.0539 | |||
| Jensen Alpha | 0.4531 | |||
| Total Risk Alpha | 0.2225 | |||
| Sortino Ratio | 0.0607 | |||
| Treynor Ratio | 0.3072 | |||
| Maximum Drawdown | 60.9 | |||
| Value At Risk | (10.60) | |||
| Potential Upside | 12.99 | |||
| Downside Variance | 59.71 | |||
| Semi Variance | 50.91 | |||
| Expected Short fall | (6.89) | |||
| Skewness | 1.02 | |||
| Kurtosis | 5.1 |
Consider CytoMed Therapeutics' intraday indicators
CytoMed Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of CytoMed Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
CytoMed Therapeutics Corporate Filings
6K | 6th of January 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 24th of June 2024 Other Reports | ViewVerify | |
| 22nd of April 2024 Other Reports | ViewVerify |
CytoMed Stock media impact
Far too much social signal, news, headlines, and media speculation about CytoMed Therapeutics that are available to investors today. That information is available publicly through CytoMed media outlets and privately through word of mouth or via CytoMed internal channels. However, regardless of the origin, that massive amount of CytoMed data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of CytoMed Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of CytoMed Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to CytoMed Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive CytoMed Therapeutics alpha.
CytoMed Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards CytoMed Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
CytoMed Therapeutics Corporate Directors
| Jieming Zeng | Chief Director | Profile | |
| Tien Luk | Chief Director | Profile | |
| Jieming MD | Chief Director | Profile | |
| Wee Tan | COO Director | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in CytoMed Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytoMed Therapeutics. If investors know CytoMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytoMed Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.22) | Revenue Per Share | Quarterly Revenue Growth (0.21) | Return On Assets | Return On Equity |
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between CytoMed Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytoMed Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.